论文部分内容阅读
胰高糖素样肽1(Glucagon-like peptide-1,GLP-1)类似物利拉鲁肽于2009年上市,在此之前的治疗措施难以有效阻止胰岛B细胞功能的进行性衰退和维持长期稳定的血糖控制达标,而且治疗过程还可能带来消化道反应、体重增加及低血糖等不良反应。利拉鲁肽可降低2型糖尿病(T2DM)患者的体重,改善β细胞功能,为T2DM的治疗带来了新的希望。本文就利拉鲁肽的研究进展做一综述。1 GLP-1早在19世纪初,人们就发现食物(特别是碳水化合物)可以刺激肠道(小肠和大肠结合部)产生促进胰岛素分泌的激素,称为肠促胰岛素,主要有葡萄糖依赖性促胰岛素激素(Glucose-
The liraglutide, an analog of Glucagon-like peptide-1 (GLP-1), was marketed in 2009 and previous treatment was not effective in stopping the progressive decline of islet B cell function and maintaining long-term Stable blood sugar control standards, and the treatment process may also cause gastrointestinal reactions, weight gain and hypoglycemia and other adverse reactions. Liraglutide can reduce the body weight of patients with type 2 diabetes mellitus (T2DM) and improve β-cell function, bringing new hope for the treatment of T2DM. This article reviews the research progress of liraglutide. As early as the early 19th century, it was discovered that food (especially carbohydrates) stimulates the gut (the small intestine and the large intestine junction) to produce a hormone that promotes insulin secretion, called incretin, and is mainly glucose-dependent Glucose-